1041004-14-1
Chemical Structure
KAI-1678
- CAS No.: 1041004-14-1
- Formula:C107H190N44O28
- Molecular Weight:2540.93
InChIKey: UVKJMACBAZMKAL-IAPYPFBNSA-N
SMILES: OC(CC[C@H](NC(C)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(NCC(NCC(N[C@H](C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: KAI-1678 is a selective protein kinase Cε (PKCε) inhibitor that competitively blocks the binding of PKCε to its anchoring protein RACK. KAI-1678 attenuates the responses of nociceptive neurons in rodent neuropathic pain models. KAI-1678 can be used in research related to moderate to severe postoperative pain, neuropathic pain, and postherpetic neuralgia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KAI-1678 | KAI-1678 is a selective protein kinase Cε (PKCε) inhibitor that competitively blocks the binding of PKCε to its anchoring protein RACK. KAI-1678 attenuates the responses of nociceptive neurons in rodent neuropathic pain models. KAI-1678 can be used in research related to moderate to severe postoperative pain, neuropathic pain, and postherpetic neuralgia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Cousins MJ, et al. The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain medicine (Malden, Mass.). 2013 Apr;14(4):533-40. [Content Brief]
- [2]. Yonezawa T, et al. PKC delta and epsilon in drug targeting and therapeutics. Recent patents on DNA & gene sequences. 2009;3(2):96-101. [Content Brief]
- [3]. Leppänen T, et al. Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example. Basic & clinical pharmacology & toxicology. 2014 Jan;114(1):37-43. [Content Brief]
Keywords
